| アブストラクト | Two different Janus kinase (JAK) inhibitors-baricitinib and tofacitinib-are effective and licensed in active rheumatoid arthritis (RA). There have been recent concerns about potential thromboembolic risks with these drugs. Concerns about baricitinib focus on clinical trial findings. Using all publically available data, we estimate thromboembolic risks are approximately five events per 1000 patient years with 4 mg baricitinib daily. Concerns about tofacitinib have been raised by analyses of the Federal Drug Administration Adverse Event Reporting System (FAERs). These show some evidence of increased risks of pulmonary thrombosis, though not pulmonary embolism or venous thrombosis. Observational studies suggest in the general population and non-RA controls there are one to four thromboembolic events per 1000 patient years. In RA, thromboembolic risks increase to three to seven per 1000 patient years. The impact of biologics and disease-modifying anti-rheumatic drugs (DMARDs) on disease risk appears minimal, and the number of thromboembolic events is between four and eight per 1000 patient years. In the short term, full details of thromboembolic events in trials of JAK inhibitors need to be published. As the numbers of thromboembolic events will be small and patients enrolled in trials are not representative of all RA patients who may receive JAK inhibitors, this information is unlikely to provide definitive answers. Consequently, in the longer term, large observational studies are needed to accurately quantify thromboembolic risks attributable to JAK inhibitors and other drugs used to treat RA, and differentiate these from risks attributable to RA itself and its comorbidities. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2018/3/4 |
|---|
| 投稿者 | Scott, Ian C; Hider, Samantha L; Scott, David L |
|---|
| 組織名 | Research Institute for Primary Care & Health Sciences, Primary Care Sciences,;Keele University, Keele, Staffordshire, UK.;Haywood Academic Rheumatology Centre, Haywood Hospital, High Lane, Burslem,;Staffordshire, UK.;Academic Rheumatology, King's College Hospital, London, UK. d.scott1@nhs.net. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29500799/ |
|---|
